logo-loader
viewRedHill Biopharma

Redhill BioPharma presents at the Proactive One2One virtual conference

RedHill Biopharma Ltd's (Nasdaq: RDHL) Guy Goldberg pitches to investors at the Proactive One2One virtual conference.

The company is a specialty biopharmaceutical company focussed on gastrointestinal and infectious diseases.

They promote several GI drugs in the U.S with a robust late-stage development pipeline.

Quick facts: RedHill Biopharma

Price: 9.5 USD

NASDAQ:RDHL
Market: NASDAQ
Market Cap: $395.08 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of RedHill Biopharma named herein, including the promotion by the Company of RedHill Biopharma in any Content on the Site, the Company receives...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

RedHill Biopharma (NASDAQ:RDHL) announces first patient dosed in U.S. Phase...

RedHill Biopharma's (NASDAQ:RDHL) (FRA:2RH) Gilead Raday, Chief Operations officer talks to Proactive London's Katie Pilbeam about announcing the dosing of the first patient in RedHill’s U.S. Phase 2/3 COVID-19 study with RHB-107. The study is evaluating the safety and efficacy of RHB-107 in...

1 week, 3 days ago

2 min read